The FDA Has Approved New Trials for the Use of Ecstasy for PTSD Patients

The Food and Drug Administration (FDA) gave the go-ahead Tuesday for large-scale clinical trials of MDMA for the treatment of posttraumatic stress disorder.

MDMA — better known as Ecstasy — will be part of phase 3 clinical trials, a final step before the party drug is potentially approved as a prescription drug for the treatment of PTSD, the New York Times reports. If approved, Ecstasy could become a prescription drug by 2021.